Zhengye Biotechnology (ZYBT) Competitors $7.61 -0.79 (-9.40%) As of 08/14/2025 03:21 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ZYBT vs. ARDX, PRAX, AMPH, COLL, VERV, AKBA, RCUS, SYRE, GPCR, and PROKShould you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Ardelyx (ARDX), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), Collegium Pharmaceutical (COLL), Verve Therapeutics (VERV), Akebia Therapeutics (AKBA), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Structure Therapeutics (GPCR), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry. Zhengye Biotechnology vs. Its Competitors Ardelyx Praxis Precision Medicines Amphastar Pharmaceuticals Collegium Pharmaceutical Verve Therapeutics Akebia Therapeutics Arcus Biosciences Spyre Therapeutics Structure Therapeutics ProKidney Zhengye Biotechnology (NASDAQ:ZYBT) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Do institutionals and insiders hold more shares of ZYBT or ARDX? 58.9% of Ardelyx shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor ZYBT or ARDX? In the previous week, Ardelyx had 15 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 16 mentions for Ardelyx and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.88 beat Ardelyx's score of 0.83 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Overall Sentiment Zhengye Biotechnology Very Positive Ardelyx Positive Do analysts prefer ZYBT or ARDX? Ardelyx has a consensus price target of $11.50, suggesting a potential upside of 96.92%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ZYBT or ARDX more profitable? Zhengye Biotechnology has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Zhengye Biotechnology's return on equity of 0.00% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Ardelyx -14.60%-36.57%-13.42% Which has better earnings and valuation, ZYBT or ARDX? Zhengye Biotechnology has higher earnings, but lower revenue than Ardelyx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$25.53M14.06$1.55MN/AN/AArdelyx$333.61M4.22-$39.14M-$0.23-25.39 SummaryArdelyx beats Zhengye Biotechnology on 8 of the 14 factors compared between the two stocks. Get Zhengye Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYBT vs. The Competition Export to ExcelMetricZhengye BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$396.20M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2825.74Price / Sales14.06356.37460.47115.79Price / Cash81.5243.0338.2159.48Price / Book7.468.608.856.15Net Income$1.55M-$54.65M$3.25B$265.06M7 Day Performance46.07%5.86%3.72%2.60%1 Month Performance36.87%8.86%5.86%2.83%1 Year PerformanceN/A13.33%30.34%25.58% Zhengye Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYBTZhengye BiotechnologyN/A$7.61-9.4%N/AN/A$396.20M$25.53M0.00278Positive NewsGap DownARDXArdelyx4.4265 of 5 stars$5.13+16.9%$11.33+120.9%+2.8%$1.05B$333.61M-22.3090Options VolumeHigh Trading VolumePRAXPraxis Precision Medicines1.8554 of 5 stars$47.79-6.5%$95.22+99.3%-6.9%$1.04B$8.55M-3.89110AMPHAmphastar Pharmaceuticals3.1988 of 5 stars$21.44+0.2%$32.33+50.8%-28.8%$1.01B$731.97M7.772,028Analyst UpgradeCOLLCollegium Pharmaceutical2.7537 of 5 stars$31.10+0.0%$43.75+40.7%+8.3%$998.98M$631.45M25.49210Insider TradeGap DownVERVVerve Therapeutics2.9506 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110AKBAAkebia Therapeutics3.9854 of 5 stars$3.72-1.1%$6.75+81.5%+143.7%$987.51M$160.18M-17.71430RCUSArcus Biosciences2.236 of 5 stars$9.55+3.5%$21.29+122.9%-32.1%$977.32M$258M-2.28500SYRESpyre Therapeutics3.1061 of 5 stars$16.87+4.4%$53.40+216.5%-31.8%$974.05M$890K-4.4773Positive NewsGPCRStructure Therapeutics2.4785 of 5 stars$16.68-0.6%$76.17+356.6%-48.9%$962.21MN/A-19.17136PROKProKidney3.2812 of 5 stars$3.18-2.5%$6.25+96.5%+6.1%$954.19M$80K-5.303News CoverageEarnings ReportShort Interest ↓Gap Down Related Companies and Tools Related Companies ARDX Alternatives PRAX Alternatives AMPH Alternatives COLL Alternatives VERV Alternatives AKBA Alternatives RCUS Alternatives SYRE Alternatives GPCR Alternatives PROK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYBT) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access